explore -WSS

explore

author：knowledge 2025-09-28 18:47:41 - browse：2264

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： AI generated plenty of interest at JPM but not a lot of trust

WSS

Test for long Covid? Researchers find new clue in blood samples

Vertex non

FDA drug safety: Singulair case shows systemic surveillance flaws

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Congressmen charge Covid hearing ‘could have been an email’

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Wikipedia

explore

Wikipedia

New air purifier tech could be key to improving indoor air quality

Time to name cancers by genetics, not organ of origin, expert says

Wildfire smoke exposes gaps in outdoor worker protections

Francis Collins on trust in science and how Covid communications failed

New air purifier tech could be key to improving indoor air quality

General Catalyst, Summa Health deal will turn on physician buy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biotech venture capitalists face new demands from investors

Walensky prepares to leave CDC — and Congress — behind

Novo Nordisk to expand supply of Wegovy for U.S. patients

leisure time

Time to name cancers by genetics, not organ of origin, expert says

How digital therapeutics firms are pivoting after Pear's bankruptcy

A $475,000 price tag for a new cancer drug: crazy or meh?

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

What we need to know about Arena Bioworks

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Wikipedia

knowledge

focus

knowledge